Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 8/20 | 0.41 |
| ▸ | HTR2C | P28335 | 8/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373942 | 0.94 | GUSB (0.44) | HTR6GUSBHTR7HTR2CHTR2A | |
| SCHEMBL12373935 | 0.93 | GUSB (0.40) | HTR6GUSBHTR7HTR2CHTR2A | |
| SCHEMBL2277665 | 0.90 | S1PR1 (0.42) | HTR6GUSBHTR7HTR2CHTR2A | |
| SCHEMBL12373925 | 0.89 | HTR7 (0.45) | HTR6GUSBHTR7HTR2CHTR2A | |
| SCHEMBL12161083 | 0.88 | S1PR1 (0.51) | HTR6GUSBHTR7HTR2CHTR2A | |
| SCHEMBL12373920 | 0.88 | HTR2C (0.43) | HTR6HTR7HTR2CHTR2ADRD3 | |
| SCHEMBL12373927 | 0.85 | BRD4 (0.41) | HTR6HTR7HTR2CHTR2ADRD3 | |
| SCHEMBL12373792 | 0.84 | S1PR1 (0.45) | HTR6S1PR1SMN1; SMN2S1PR3 | |
| SCHEMBL12373827 | 0.83 | S1PR1 (0.42) | GUSBHTR7S1PR1SMN1; SMN2S1PR3 | |
| SCHEMBL12162129 | 0.83 | HTR6 (0.46) | HTR6GUSBHTR7HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | S1PR1, S1PR3, S1PR2 | HTR6 1705/4885GUSB 4631/4885HTR7 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.